Shares of Bruker Co. (NASDAQ:BRKR) have been given a consensus recommendation of “Hold” by the fourteen brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $51.22.
Several analysts recently issued reports on the stock. ValuEngine cut shares of Bruker from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. BidaskClub cut shares of Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and upped their price objective for the company from $32.00 to $48.00 in a research note on Monday, July 15th. Needham & Company LLC set a $58.00 price objective on shares of Bruker and gave the company a “buy” rating in a research note on Friday, September 27th. Finally, Bank of America raised shares of Bruker from a “neutral” rating to a “buy” rating and set a $52.00 price objective for the company in a research note on Thursday, September 26th.
In other news, CEO Burkhard Prause sold 15,702 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $42.96, for a total value of $674,557.92. Following the completion of the sale, the chief executive officer now owns 1,338 shares of the company’s stock, valued at approximately $57,480.48. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Mark Munch sold 47,203 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $42.87, for a total transaction of $2,023,592.61. Following the completion of the sale, the vice president now directly owns 96,063 shares of the company’s stock, valued at approximately $4,118,220.81. The disclosure for this sale can be found here. Corporate insiders own 26.50% of the company’s stock.
NASDAQ BRKR traded down $0.21 during trading hours on Monday, hitting $43.52. 292,200 shares of the company’s stock traded hands, compared to its average volume of 774,672. Bruker has a 52-week low of $26.10 and a 52-week high of $51.41. The company has a market capitalization of $6.76 billion, a PE ratio of 31.09, a PEG ratio of 2.15 and a beta of 1.39. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.19 and a quick ratio of 1.27. The firm’s 50-day moving average is $43.16 and its 200-day moving average is $43.33.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, August 1st. The medical research company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. Bruker had a net margin of 9.57% and a return on equity of 27.10%. The company had revenue of $490.20 million during the quarter, compared to analysts’ expectations of $477.70 million. During the same quarter in the prior year, the company earned $0.25 EPS. Bruker’s revenue was up 10.5% compared to the same quarter last year. Equities research analysts predict that Bruker will post 1.61 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Tuesday, September 3rd were paid a $0.04 dividend. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.16 annualized dividend and a dividend yield of 0.37%. Bruker’s dividend payout ratio (DPR) is 11.43%.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.